Skip to main content
Log in

The clinical significance evaluation of serum β2-microglobulin for thyroid cancer patients

The Chinese-German Journal of Clinical Oncology

Abstract

Objective

The aim of this study was to investigate the clinical value and relevance on the serum β2-microglobulin (β2-MG) of patients with thyroid cancer.

Methods

One thousand and two normal cases, 95 thyroid cancer patients and 243 nodular goiter patients were selected to measure serum β2-MG levels using double-antibody sandwich enzyme-linked immunosorbent assay (ELISA).

Results

The positive rate of 7.78% in normal population (78/1002) and 31.57% in thyroid cancer patients (30/95). There were significant differences between the normal population and thyroid cancer patients (χ 2 = 55.352; P = 0.000). The positive rate of 7.81% in nodular goiter patients (19/243) and there were no significant differences between the normal population and nodular goiter patients (χ 2 = 0.0004; P = 0.986), but significant differences between nodular goiter patients and thyroid cancer patients (χ 2 = 31.106; P = 0.000). Meanwhile, the significant difference of the positive rate existed in between the various pathological types of thyroid cancer (χ 2 = 10.015; P = 0.007), anaplastic thyroid cancer patients with the highest positive rate and The significant difference was found between the positive lymph node metastasis groups and negative lymph node metastasis groups (χ 2 = 4.441; P = 0.035), the presence of distant metastasis group and absence of distant metastasis group (χ 2 = 9.795; P = 0.002).

Conclusion

Serum β2-MG levels and prognosis of thyroid cancer patients was negatively correlated. It showed important clinical value to detect the level of β2-MG in the early diagnosis, prognosis and the clinical observation for thyroid cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cao MG, Auge JM, Molina R, et al. Melanoma inhibiting activity protein (MIA), beta-2 microglobulin and lactate dehydrogenase (LDH) in metastatic melanoma. Anticancer Res, 2007, 27: 595–599.

    PubMed  CAS  Google Scholar 

  2. Chinese Medical Association. Clinical guidelines for diagnosis and treatment (tumors section). Beijing: People’s Medical Publishing House, 2005. 46–52.

    Google Scholar 

  3. Du HF, Li KS, Lian XW, et al. Production and identification of monoclonal antibodies against β2-microglobulin. Chin Med Her (Chinese), 2008, 4: 36–37.

    Google Scholar 

  4. Josson S, Nomura T, Lin JT, et al. β2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. Cancer Res, 2011, 71: 2600–2610.

    Article  PubMed  CAS  Google Scholar 

  5. Yang C, Lan TB, Cheng Y. Renal impairment in multiple myelomas. Chinese-German J Clin Oncol, 2011, 10: 418–422.

    Article  Google Scholar 

  6. Chen CH, Su CY, Chien CY, et al. Overexpression of beta2-microglobulin is associated with poor survival in patients with oral cavity squamous cell carcinoma and contributes to oral cancer cell migration and invasion. Br J Cancer, 2008, 99: 1453–1461.

    Article  PubMed  CAS  Google Scholar 

  7. Nomura T, Huang WC, Seo S, et al. Targeting beta2-microglobulin mediated signaling as a novel therapeutic approach for human renal cell carcinoma. J Urol, 2007, 178: 292–300.

    Article  PubMed  CAS  Google Scholar 

  8. Liu QJ, Tian YX, Li HP. Correlativity of lymph node micrometastases detection in follicular carcinoma of thyroid in different risk groups. Chinese-German J Clin Oncol, 2009, 8: 699–701.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Qinjiang Liu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ma, S., Liu, Q. & Li, K. The clinical significance evaluation of serum β2-microglobulin for thyroid cancer patients. Chin. -Ger. J. Clin. Oncol. 11, 271–273 (2012). https://doi.org/10.1007/s10330-012-0960-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10330-012-0960-6

Key words

Navigation